CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

Hideki Muramatsu; Yoshiyuki Takahashi; Yoshie Shimoyama; Sayoko Doisaki; Nobuhiro Nishio; Yoshinori Ito; Asahito Hama; Akira Shimada; Hiroshi Yagasaki; Masafumi Ito; Seiji Kojima

doi:10.1007/s12185-011-0870-3

CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

Hideki Muramatsu, Yoshiyuki Takahashi, Yoshie Shimoyama, Sayoko Doisaki, Nobuhiro Nishio, Yoshinori Ito, Asahito Hama, Akira Shimada, Hiroshi Yagasaki, Masafumi Ito, Seiji Kojima

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.

Original language	English
Pages (from-to)	779-781
Number of pages	3
Journal	International journal of hematology
Volume	93
Issue number	6
DOIs	https://doi.org/10.1007/s12185-011-0870-3
Publication status	Published - Jun 2011
Externally published	Yes

Keywords

Aplastic anemia
CD20
Epstein-Barr virus
Post-transplant lymphoproliferative disease
Rituximab
Unrelated bone marrow transplantation

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s12185-011-0870-3

Cite this

Muramatsu, H., Takahashi, Y., Shimoyama, Y., Doisaki, S., Nishio, N., Ito, Y., Hama, A., Shimada, A., Yagasaki, H., Ito, M., & Kojima, S. (2011). CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. International journal of hematology, 93(6), 779-781. https://doi.org/10.1007/s12185-011-0870-3

CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. / Muramatsu, Hideki; Takahashi, Yoshiyuki; Shimoyama, Yoshie; Doisaki, Sayoko; Nishio, Nobuhiro; Ito, Yoshinori; Hama, Asahito; Shimada, Akira; Yagasaki, Hiroshi; Ito, Masafumi; Kojima, Seiji.

In: International journal of hematology, Vol. 93, No. 6, 06.2011, p. 779-781.

Research output: Contribution to journal › Article › peer-review

Muramatsu, H, Takahashi, Y, Shimoyama, Y, Doisaki, S, Nishio, N, Ito, Y, Hama, A, Shimada, A, Yagasaki, H, Ito, M & Kojima, S 2011, 'CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia', International journal of hematology, vol. 93, no. 6, pp. 779-781. https://doi.org/10.1007/s12185-011-0870-3

Muramatsu, Hideki ; Takahashi, Yoshiyuki ; Shimoyama, Yoshie ; Doisaki, Sayoko ; Nishio, Nobuhiro ; Ito, Yoshinori ; Hama, Asahito ; Shimada, Akira ; Yagasaki, Hiroshi ; Ito, Masafumi ; Kojima, Seiji. / CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. In: International journal of hematology. 2011 ; Vol. 93, No. 6. pp. 779-781.

@article{edd7020ebd4d4e2ab063a4ca61afbccc,

title = "CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia",

abstract = "Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.",

keywords = "Aplastic anemia, CD20, Epstein-Barr virus, Post-transplant lymphoproliferative disease, Rituximab, Unrelated bone marrow transplantation",

author = "Hideki Muramatsu and Yoshiyuki Takahashi and Yoshie Shimoyama and Sayoko Doisaki and Nobuhiro Nishio and Yoshinori Ito and Asahito Hama and Akira Shimada and Hiroshi Yagasaki and Masafumi Ito and Seiji Kojima",

year = "2011",

month = jun,

doi = "10.1007/s12185-011-0870-3",

language = "English",

volume = "93",

pages = "779--781",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "6",

}

TY - JOUR

T1 - CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

AU - Muramatsu, Hideki

AU - Takahashi, Yoshiyuki

AU - Shimoyama, Yoshie

AU - Doisaki, Sayoko

AU - Nishio, Nobuhiro

AU - Ito, Yoshinori

AU - Hama, Asahito

AU - Shimada, Akira

AU - Yagasaki, Hiroshi

AU - Ito, Masafumi

AU - Kojima, Seiji

PY - 2011/6

Y1 - 2011/6

N2 - Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.

AB - Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.

KW - Aplastic anemia

KW - CD20

KW - Epstein-Barr virus

KW - Post-transplant lymphoproliferative disease

KW - Rituximab

KW - Unrelated bone marrow transplantation

UR - http://www.scopus.com/inward/record.url?scp=79960079358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960079358&partnerID=8YFLogxK

U2 - 10.1007/s12185-011-0870-3

DO - 10.1007/s12185-011-0870-3

M3 - Article

C2 - 21559814

AN - SCOPUS:79960079358

VL - 93

SP - 779

EP - 781

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 6

ER -

CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this